Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:AVDLNASDAQ:IBBNASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$18.50+6.6%$16.67$5.88▼$23.64$4.37B0.63.33 million shs3.96 million shsAVDLAvadel Pharmaceuticals$7.96-0.5%$8.46$7.39▼$19.09$769.17M1.571.19 million shs857,375 shsIBBiShares Biotechnology ETF$134.25+0.2%$136.24$123.60▼$150.57$6.34B0.841.34 million shs1.19 million shsSANASana Biotechnology$2.92+6.2%$2.98$1.52▼$10.50$651.95M1.632.97 million shs1.94 million shs7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+6.63%+4.64%+11.04%-0.91%+197.43%AVDLAvadel Pharmaceuticals-0.50%+1.14%-12.43%-24.98%-50.16%IBBiShares Biotechnology ETF+0.19%-1.86%-1.40%-2.48%-2.75%SANASana Biotechnology+6.18%+14.51%+6.96%+43.14%-68.50%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.2375 of 5 stars2.61.00.00.03.31.71.9AVDLAvadel Pharmaceuticals3.8121 of 5 stars4.53.00.00.02.73.30.6IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AN/AN/ASANASana Biotechnology2.982 of 5 stars3.43.00.00.01.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$22.5021.62% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$19.88149.69% UpsideIBBiShares Biotechnology ETF 0.00N/AN/AN/ASANASana Biotechnology 2.80Moderate Buy$14.00379.45% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, IBB, SANA, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2025ADMAADMA BiologicsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.003/4/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/3/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.002/11/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.001/13/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $14.001/10/2025AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $13.001/10/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $21.001/9/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.001/8/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.001/8/2025SANASana BiotechnologyTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M10.25$0.06 per share311.70$0.60 per share30.83AVDLAvadel Pharmaceuticals$169.12M4.55N/AN/A$0.98 per share8.12IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/A$1.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8266.0726.81N/A17.80%53.20%26.07%5/8/2025 (Estimated)AVDLAvadel Pharmaceuticals-$160.28M-$0.52N/A132.67N/A-52.53%-93.34%-44.77%5/6/2025 (Estimated)IBBiShares Biotechnology ETFN/AN/A24.52∞N/AN/AN/AN/AN/ASANASana Biotechnology-$283.26M-$1.40N/AN/AN/AN/A-84.22%-44.97%3/13/2025 (Estimated)Latest AVDL, IBB, SANA, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2025N/ASANASana Biotechnology-$0.22N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AIBBiShares Biotechnology ETF$0.380.28%N/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ALatest AVDL, IBB, SANA, and ADMA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date12/16/2024IBBiShares Biotechnology ETF$0.062412/17/202412/17/202412/20/2024(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26AVDLAvadel PharmaceuticalsN/A2.972.60IBBiShares Biotechnology ETFN/AN/AN/ASANASana BiotechnologyN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AVDLAvadel Pharmaceuticals69.19%IBBiShares Biotechnology ETF62.45%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%AVDLAvadel Pharmaceuticals4.80%IBBiShares Biotechnology ETFN/ASANASana Biotechnology31.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530236.39 million227.64 millionOptionableAVDLAvadel Pharmaceuticals7096.63 million91.74 millionOptionableIBBiShares Biotechnology ETFN/A47.25 millionN/AOptionableSANASana Biotechnology380223.27 million153.83 millionOptionableAVDL, IBB, SANA, and ADMA HeadlinesRecent News About These CompaniesSana Biotechnology (NASDAQ:SANA) Trading Up 9.7% - What's Next?March 12 at 6:18 PM | marketbeat.comSana Biotechnology options imply 6.3% move in share price post-earningsMarch 7, 2025 | markets.businessinsider.comIs Sana Biotechnology (SANA) Among Jeff Bezos’ Investments in 2025?March 4, 2025 | insidermonkey.comSana Biotechnology (SANA) Projected to Post Quarterly Earnings on ThursdayMarch 4, 2025 | americanbankingnews.comSana Biotechnology (SANA) Expected to Announce Earnings on ThursdayMarch 4, 2025 | marketbeat.comWhy Sana Biotechnology, Inc. (SANA) is Skyrocketing So Far in 2025March 1, 2025 | insidermonkey.comSana Biotechnology (NASDAQ:SANA) Trading 6.3% Higher - Still a Buy?February 28, 2025 | marketbeat.comSana Biotechnology (SANA) to Release Quarterly Earnings on ThursdayFebruary 27, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Shares Down 8.9% - Should You Sell?February 25, 2025 | marketbeat.comSana Biotechnology to Present at the Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comSana Biotechnology, Inc. (SANA)February 23, 2025 | finance.yahoo.comSana Biotechnology (NASDAQ:SANA) Shares Up 9.8% - Here's What HappenedFebruary 15, 2025 | marketbeat.comRetail Traders Flocked To These 5 Biotech Stocks In January — Here’s WhyJanuary 31, 2025 | msn.comWhat’s Behind the -4.69% Drop in Sana Biotechnology Inc (SANA) Stock? Find Out Now!January 31, 2025 | bovnews.comTD Cowen Just Upgraded Sana Biotechnology Inc (SANA) Stock—What Does This Mean for Investors?January 28, 2025 | bovnews.comSana Biotechnology, Inc. (SANA): A Bull Case TheoryJanuary 28, 2025 | insidermonkey.comSana Biotechnology Inc (SANA) Stock Trading RecapJanuary 24, 2025 | bovnews.comIs Sana Biotechnology, Inc. (SANA) the Hottest Smid-Cap Stock So Far In 2025?January 23, 2025 | msn.comWhy Did Sana Biotechnology Inc (SANA) Stock Tumble -7.59% to $2.92?January 23, 2025 | bovnews.comThe Sana Biotechnology Inc Stock Thriller: Decoding the Mystery Behind SANA’s Recent MovementsJanuary 21, 2025 | bovnews.comThere May Still Be Time to Get in on These 3 Trending Biotechs (SANA)January 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentBy Gabriel Osorio-Mazilli | February 14, 2025View NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentArcher Aviation Stock Skids: Mistaking Progress for Bad News?By Chris Markoch | February 24, 2025View Archer Aviation Stock Skids: Mistaking Progress for Bad News? 3 Companies Buying Back Stock—Why It MattersBy Gabriel Osorio-Mazilli | March 12, 2025View 3 Companies Buying Back Stock—Why It MattersAVDL, IBB, SANA, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$18.50 +1.15 (+6.63%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$18.66 +0.16 (+0.84%) As of 03/12/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Avadel Pharmaceuticals NASDAQ:AVDL$7.96 -0.04 (-0.50%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$7.96 0.00 (0.00%) As of 03/12/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.iShares Biotechnology ETF NASDAQ:IBB$134.25 +0.26 (+0.19%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$134.00 -0.25 (-0.18%) As of 03/12/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Sana Biotechnology NASDAQ:SANA$2.92 +0.17 (+6.18%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$2.82 -0.10 (-3.42%) As of 03/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
